Tesamorelin Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for Tesamorelin. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
Tesamorelin literature includes nonclinical pharmacology and reviews of the approved medicine context. Those records are separate from a research-use catalog item.
Questions covered by the selected literature
- What nonclinical pharmacology evaluated
- How review articles describe the growth-hormone-releasing-factor analogue
- Why approved-drug literature cannot be transferred to a research-use product
Evidence limits
The source record includes nonclinical and approved-medication context. BioPep USA does not provide clinical or product-use guidance.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.. Basic Clin Pharmacol Toxicol. 2007 Jan. PMID: 17214611.
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.. Ann Pharmacother. 2012 Feb. PMID: 22298602.
- Tesamorelin.. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf chapter, updated October 20, 2018. PMID: 31644039.
BioPep USA record
BioPep USA currently lists Tesamorelin. Use the product page for current options and the documentation page for lot records.
Last reviewed: September 15, 2026.
